Innoviva Q4 revenue up 25% to $114.6M; net income $164.2M; NUZOLVENCE approved

Innoviva, Inc.

2025-FY EPS reported $3.30 revenue$411,328,000

Full year 2025 revenue $411.3M (+15% YoY); net income $271.2M ($4.02 basic EPS).
Royalty revenue from GSK $250.3M; IST U.S. net product sales $119.2M (+47% YoY).
FDA approved NUZOLVENCE (zoliflodacin) for uncomplicated gonorrhea in Dec 2025.
Guidance: IST U.S. net product sales at least $150M in 2026.
$125M repurchase program initiated; 797,298 shares repurchased for $16.0M as of year-end.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.